- Molecular NameEtretinate
- SynonymNA
- Weight354.49
- Drugbank_IDN/A
- ACS_NO54350-48-0
- Show 3D model
- LogP (experiment)5.59
- LogP (predicted, AB/LogP v2.0)6.43
- pkaN/A
- LogD (pH=7, predicted)6.43
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.89
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds8
- TPSA35.53
- StatusUS withdrawn
- AdministrationN/A
- PharmacologyA medication used to treat severe psoriasis.
- Absorption_valueN/A
- Absorption (description)Etretinate is rapidly absorbed after an initial lag time of approx. 1 h following oral administration. Peak plasma concentrations occur after about 2 to 6 h. Absorption is increased by administration with milk or fatty food.
- Caco_2N/A
- Bioavailability40.0
- Protein binding99.0
- Volume of distribution (VD)40 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Blood:plasma ratio, 0.60. Red blood cell:plasma, 0.11.
- MetabollsmThe drug undergoes significant first-pass metabolism (hydrolysis) and the active metabolite is acitretin (the carboxyl acid, Ro 10-1670) which may itself be metabolised to etretinate. Subsequent metabolism occurs to inactive 13-cis-acitretin (Ro 13-7652, the major metabolite in blood following multiple dosing) and other metabolites. Etretinate accumulates in adipose tissue (especially in liver and subcutaneous fat) after repeated dosing; detectable concentrations have been found in serum up to 3 years after discontinuation of therapy.
- Half life120 days
- ExcretionUp to 75% of a dose is excreted via bile in faeces mainly as the unchanged drug, acitretin, β-glucuronides and other minor metabolites (18 metabolites have been identified in total). It is also excreted in urine as metabolites. No intact drug is present in urine. It crosses the placenta and is distributed into breast milk.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityEtretinate is teratogenic at therapeutic doses.
- LD50 (rat)N/A
- LD50 (mouse)N/A